Stratification of the patient cohort into early (stage I/II) and late (stage III/IV) showed that SCNN1B promoter methylation is associated with poor survival in early (P < 0.007) and late CRC (P < 0.044) (Fig. 2G). This evidence concerns the gene SCNN1B and colorectal carcinoma.